Carbachol/Brimonidine Tartrate

卡巴胆碱/酒石酸溴莫尼定

Report date: 2026/02/14 20:00:22

Base Information

Drug NameCarbachol/Brimonidine Tartrate
Drug Alias NameBRIMOCHOLBRIMOCHOL PFYUVEZZIVT-001VTI-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor agonistsAdrenergic receptors alpha-2 agonists
TargetsMuscarinic acetylcholine receptorAdrenergic receptors alpha-2
Therapy Area/IndicationsPresbyopia
Global Approved IndicationsPresbyopia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/01/28
Country/TerritoryUnited StatesMainland China
CombinationsYes CarbacholBrimonidine Tartrate
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesVisus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTenpoint Therapeutics LtdRitedose Corporation IncVisus Therapeutics Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPresbyopia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A